[Federal Register Volume 78, Number 215 (Wednesday, November 6, 2013)]
[Notices]
[Pages 66751-66752]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-26612]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of Science Policy, Office of Biotechnology Activities;
Recombinant or Synthetic Nucleic Acid Molecule Research: Action Under
the NIH Guidelines for Research Involving Recombinant or Synthetic
Nucleic Acid Molecules (NIH Guidelines)
AGENCY: NIH, Public Health Service, HHS.
ACTION: Notice of Final Action under the NIH Guidelines.
-----------------------------------------------------------------------
SUMMARY: The Office of Biotechnology Activities (OBA) is updating
Appendix B (Classification of Human Etiologic Agents on the Basis of
Hazard) of the NIH Guidelines by specifying the risk group (RG)
classification for two organisms: Middle East Respiratory Syndrome
coronavirus (MERS-CoV) and Pseudomonas aeruginosa.
Background: The NIH Guidelines provide guidance to investigators
and local Institutional Biosafety Committees (IBCs) for setting
containment for research involving recombinant or synthetic nucleic
acid molecules. Section II-A, Risk Assessment, instructs investigators
and IBCs to make an initial risk assessment based on the RG of the
agent that will be manipulated (see Appendix B, Classification of Human
Etiologic Agents on the Basis of Hazard). The RG of the agent often
correlates with the minimum containment level required for experiments
subject to the NIH Guidelines. Updating Appendix B by revising the risk
groups for certain organisms, or adding new organisms, leads to more
uniform containment recommendations that are commensurate with the
biosafety risk.
The resulting amendments are ``Minor Actions'' under Section IV-C-
1-(b)-2 of the NIH Guidelines and, therefore, will be implemented
immediately upon publication in the Federal Register. However, the OBA
welcomes public comment to inform any future changes to Appendix B.
DATES: Comments may be submitted to the OBA in paper or electronic form
at the mailing, fax, and email addresses shown below under the heading
``For Further Information.'' All comments should be submitted by
December 6, 2013. All written comments received in response to this
notice will be available for public inspection in the NIH OBA office,
6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985,
weekdays between the hours of 8:30 a.m. and 5:00 p.m.
FOR FURTHER INFORMATION CONTACT: If you have questions, or require
additional information about these changes, please contact the OBA by
email at [email protected] or by telephone at 301-496-9838. Comments may
be submitted to the same email address or by fax to 301-496-9839 or by
mail to the Office of Biotechnology Activities, National Institutes of
Health, 6705 Rockledge Drive, Suite 750, Bethesda, Maryland 20892-7985.
Background information may be obtained by contacting the NIH OBA by
email at [email protected].
Middle East Respiratory Syndrome coronavirus (MERS-CoV)
MERS-CoV is an emerging infectious disease agent that was
originally identified in 2012 in Saudi Arabia. The virus is a member of
the order Nidovirales, family Coronaviridae, and causes a severe
pulmonary syndrome that is similar to what was seen with Severe Acute
Respiratory Syndrome coronavirus (SARS-CoV). MERS-CoV has been
identified as the cause of a severe respiratory disease in 144
individuals, of which 62 have died (as of October 25, 2013; source:
Centers for Disease Control and Prevention (CDC)--http://www.cdc.gov/coronavirus/mers/). The overall mortality rate of MERS-CoV infection to
date is about four times higher than what was reported for SARS-CoV;
although it is of note, in patients over 65 years of age, that
mortality from infection with SARS-CoV was reported to exceed 50
percent (based on World Health Organization (WHO) data accessed
September 9, 2013, http://www.who.int/csr/sars/archive/2003_05_07a/en/print.html). As was the case for SARS-CoV, there are no proven
preventive or therapeutic measures against this new virus. In addition,
there are many unanswered questions regarding this virus, including
questions about how the virus is transmitted. Although the incidence of
viral infections caused by MERS-CoV remains highest in, and largely
localized to the Arabian Peninsula (138 of 144 cases), the high
mortality rate associated with this agent and its epidemic potential
has led to close monitoring by the WHO (http://www.who.int/csr/disease/coronavirus_infections/faq/en/index.html).
[[Page 66752]]
Under Appendix B of the NIH Guidelines, most coronaviruses are
classified as RG2 viruses. Given the severity of illness seen to date,
MERS-CoV will be added to the list of RG3 agents, as was done for SARS-
CoV. However, because little is currently known about the source,
reservoir, and epidemiology of this virus, the RG classification will
be reassessed if new data emerge relevant to the biosafety risks
associated with the agent. In addition, while research with RG3 agents
is often carried out at Biosafety level 3 containment--with appropriate
enhancements depending upon the nature of the agent, e.g., increased
respiratory precautions for agents that are transmissible by the
aerosol route--the RG of an agent is not the only factor that
determines the containment level. As stated in Section II-A of the NIH
Guidelines (Risk Assessment) ``once the risk group of an agent is
identified, this should be followed by a thorough consideration of how
the agent is to be manipulated'' and there may be experiments for which
a higher containment level is warranted. Interim Laboratory Biosafety
Guidelines for Handling and Processing Specimens Associated with MERS-
CoV are available on the CDC Web site at the following URL: http://www.cdc.gov/coronavirus/mers/guidelines-lab-biosafety.html.
Pseudomonas aeruginosa
Bacteria belonging to the genus Pseudomonas are ubiquitous in the
environment. They are generally considered to be opportunistic
pathogens, i.e., able to cause disease in individuals who are
immunocompromised. According to the CDC, serious pseudomonas infections
usually occur in hospitalized patients and those who are
immunocompromised and these infections can lead to severe illness and
death (http://www.cdc.gov/hai/organisms/pseudomonas.html). Healthy
people can also become ill from Pseudomonas aeruginosa, especially
after exposure to inadequately disinfected water. Per the CDC, ``Ear
infections, especially in children, and more generalized skin rashes
may occur after exposure to inadequately chlorinated hot tubs or
swimming pools. Eye infections have occasionally been reported in
persons using extended-wear contact lenses'' (http://www.cdc.gov/hai/organisms/pseudomonas.html).
Because this bacterium generally causes mild disease in healthy
individuals and there are antibiotics to treat such disease, the OBA
will add it to Appendix B as an RG2 bacterium. This is consistent with
other assessments of the RG for this pathogen by other biosafety
guidances, including the Canadian (http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/pseudomonas-spp-eng.php) and the European Community
(http://www.bacterio.net/hazard.html#group2) guidances.
Appendix B-II-A. Risk Group 2 (RG2)--Bacterial Agents Including
Chlamydia.
The following addition will be made to Appendix B-II-A. Risk Group
2 (RG2)--Bacterial Agents Including Chlamydia:
Pseudomonas aeruginosa
The following addition will be made to Appendix B-III-D Risk Group
3 (RG3)--Viruses and Prions:
Middle East Respiratory Syndrome coronavirus (MERS-CoV)
Dated: October 30, 2013.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health
[FR Doc. 2013-26612 Filed 11-5-13; 8:45 am]
BILLING CODE 4140-01-P